Barclays Maintains an 'Overweight' Rating on Amylin Pharmaceuticals (AMLN); TRx Share Continues to Increase Byetta Losing Share in GLPs
Tweet Send to a Friend
Barclays maintains an 'Overweight' rating on Amylin Pharmaceuticals (Nasdaq: AMLN), price target $29.
Barclays analys says,"IMS Health prescription data reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analys says,"IMS Health prescription data reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
